North America to the Grab Lion’s Share in the Infectious Disease Testing Market

Introduction

Growing patient awareness about the benefits of personalized medicines is driving the adoption of molecular diagnostics, genomics, and proteomics technologies for infectious disease testing. Diagnostic tests can be used to assess the efficacy of specific therapeutic agents and treatments in patients. They help in determining the optimal dosages for drugs whose therapeutic effects vary widely depending on the patient.  

Inadequate reimbursements impede the market growth; as per the MedPac (Medicare Payment Advisory Commission), medical testing witnessed a 40% decline in reimbursements. In 2012, Medicare revised its reimbursement mechanism for some IVD tests, including infectious diseases and molecular disease tests.

The leading players are heavily investing in R&D activities to develop advanced sequencing testing. For instance, Genapsys introduced ‘Genius’ an I-pad size sequencing platform with the ability to diagnose multiple molecules in a single run. Similarly, Stratos Genomics developed a fourth-generation sequencer based on sequencing by expansion (SBX), further driving the market growth. 

Key Highlights

• The infectious disease testing market was valued at USD 16.39 billion in 2019 and is expected to grow with a CAGR of 5.72%
• By technology, the DNA sequencing & next-generation sequencing (NGS) segment is projected to grow with a remarkable CAGR due to reducing the cost of sequencing. Currently, NGS is recognized as a primary technology disease testing across the globe.
• North America leads the infectious disease testing market

Competitive Players

1. Abbott Laboratories
2. Becton
3. Biomérieux SA
4. Bio-Rad Laboratories
5. Danaher Corporation
6. Diasorin
7. Dickinson and Company
8. Luminex
9. Meridian Bioscience
10. Quidel
11. Roche Diagnostics
12. Siemens AG
13. Thermo Fisher Scientific

Recent Developments

Recent Developments

• February 2022, The EU regulatory body awarded SEEGENE's Allplex SARS-CoV-2 rapid MDx Assay the CE-IVD seal. Given that it can produce results in less than 30 minutes, the Allplex SARS-CoV-2 rapid MDx Assay is suitable for use in airports, schools, and other large-scale institutions.
• February 2022, The Actemra/RoActemra (tocilizumab) intravenous (IV) from Roche has been prequalified by the WHO for use in patients with severe or profound COVID-19.

Segmentation

1. By Product & Services
   1. Kits & reagents
   2. Instruments
   3. Software
2. By Technology
   1. Immunodiagnostics
   2. DNA Sequencing & NGS
   3. PCR
3. By End User
   1. Hospitals/Clinical Laboratories
   2. Reference Laboratories
   3. Physician Offices
   4. Academic/Research Institutes